artesunic acid has been researched along with Acute Myelogenous Leukemia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, P; Jing, Y; Wang, Y; Waxman, S; Yin, C; Zhang, J; Zhang, Z; Zhao, L | 1 |
| Huang, Z; Law, BYK; Li, H; Li, W; Liu, Y; Luo, Z; Yang, J; Yu, Y; Zhang, M | 1 |
| Chen, X; Gao, XH; Hao, HL; Huang, C; Li, J; Li, JY; Li, Y; Liu, JY; Tu, CQ; Wang, DW; Wang, RC; Xiong, X; Yang, J; Yang, YB; Yuan, J; Zhang, XX; Zhang, XY; Zheng, CF; Zou, LL | 1 |
| Dong, X; Li, W; Lu, J; Ren, J; Tao, Y; Wang, Y; Xu, H; Xue, T; Yang, J | 1 |
| Chen, Y; Huang, P; Li, H; Luo, X; Su, Q; Zhang, P | 1 |
| Chen, CC; Chu, S; Forman, SJ; Kalvala, A; Kumar, B; Marcucci, G; Pullarkat, V; Rosen, S | 1 |
| Chen, Y; Rong, Y; Su, Q; Tan, M | 1 |
| Baker, SD; Buaboonnam, J; Drenberg, CD; Fan, Y; Guy, RK; Hu, S; Li, L; Orwick, SJ; Rubnitz, J; Shelat, AA | 1 |
8 other study(ies) available for artesunic acid and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Topics: Aged; Animals; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe
Topics: Animals; Antimalarials; Apoptosis; Artesunate; Cell Line, Tumor; Female; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Reactive Oxygen Species; Receptors, Transferrin | 2023 |
Topics: Apoptosis; Artesunate; Caspase 3; Caspase 9; Cell Line; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Myeloid, Acute; Mutation; Retrospective Studies | 2022 |
Exploring underlying mechanism of artesunate in treatment of acute myeloid leukemia using network pharmacology and molecular docking.
Topics: Artesunate; Databases, Genetic; Drugs, Chinese Herbal; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Network Pharmacology | 2023 |
Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.
Topics: Artesunate; Cytarabine; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Signal Transduction; STAT3 Transcription Factor | 2023 |
Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
Topics: Animals; Antimalarials; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Drug Synergism; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Survival Rate | 2017 |
Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Artemisinins; Artesunate; Caspase 3; Caspase 8; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Evaluation of artemisinins for the treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Survival; Cytarabine; High-Throughput Screening Assays; Humans; Leukemia, Myeloid, Acute; Lysosomes; Mice, Inbred Strains; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |